Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Paradigm Biopharmaceuticals presents novel six-month data in its PARA_OA_008 Phase II clinical study

Paradigm Biopharmaceuticals presents novel six-month data in its PARA_OA_008 Phase II clinical study

Paradigm Biopharma — 2 videos in collection

More on this equity

Paradigm Biopharmaceuticals (ASX: PAR) is a late-stage drug development company that is driven to improve patients’ health and quality of life by discovering, developing and delivering pharmaceutical therapies. Paradigm’s current focus is on developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue-regenerative properties of PPS, such as in osteoarthritis (Phase III) and mucopolysaccharidosis (Phase II).
We recently held a webinar with Paradigm to discuss the Phase II six-month data from its knee osteoarthritis trial, addressing iPPS’s effect on biomarkers such as pain, knee function and disease modification. The webinar is hosted by Edison’s Soo Romanoff and includes updates from Paradigm’s Paul Rennie (founder, managing director and chair) Donna Skerrett MD (chief medical officer) and Mukesh Ahuja (global head of OA).

< Previous
Next >

You may also be interested in these:

Healthcare

Paradigm Biopharma – executive interview
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.